Kooperativer Bibliotheksverbund

UID:

Format: 1 online resource (330 pages) : , color illustrations

ISBN: 0-12-811398-7

Note: Front Cover -- Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: From Research to Bedside -- Copyright -- Contents -- Contributors -- Preface -- Chapter 1: Epidemiology of LUTS and BPH -- Economic Impact of BPH and LUTS -- Risk Factors for BPH Development -- Age -- Genetics -- Sex Steroid Hormones -- Metabolic Syndrome -- Cardiovascular Disease -- Obesity -- Diabetes and Alterations in Glucose Homeostasis -- Lipids -- Physical Activity -- Alcohol -- Smoking -- Inflammation -- Race -- References -- Chapter 2: Pathologic Triggers Related to LUTS and BPH -- Introduction -- Etiology -- Hyperplasia -- Role of Inflammation -- Prostatic Immune Cells and Inflammation -- BPH and Prostatic Inflammation -- Clinical Evidence -- Molecular Pathways -- Hormonal Pathways -- Metabolic Syndrome, Inflammation, and BPH -- Inflammation and BPH Progression -- Biomarkers of Prostatic Inflammation -- References -- Further Reading -- Chapter 3: The Relationship Between Inflammation and LUTS/BPH -- Introduction -- Pathophysiology -- The Immunochemical Pattern of BPH -- The Inflammatory Pattern of BPH -- The Origin of Chronic Prostate Inflammation -- The Role of Inflammatory Cytokines -- Chronic Inflammation and LUTS -- Prostate Inflammation and BPH Progression -- Prostate Inflammation and LUTS Deterioration -- Prostate Inflammation and Acute Urinary Retention -- Diagnostic Methods for Chronic Prostate Inflammation -- The Role of Biomarkers -- Concurrent Prostate Calcifications -- Medical History of Chronic Urinary Tract Infections -- Metabolic Syndrome-A More Recent Trend in the Etiology of LUTS/BPH. The Connection With Prostatic Inflammation -- Prostate Inflammation and Its Impact on LUTS Medication -- Conclusions -- References -- Further Reading -- Chapter 4: Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Erectile Dysfunction. , Anatomy and Physiology of Erectile Dysfunction -- Epidemiology and Risk Factors of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Erectile Dysfunction -- Age -- Sedentary Lifestyle and Lack of Exercise -- Cigarette Smoking -- Excessive Alcohol Intake -- Depression -- Hypertension and Cardiovascular Disease -- Hyperlipidemia -- Type 2 Diabetes Mellitus -- Obesity/Waist Circumference -- Hypogonadism -- Genetic Predisposition -- Pathophysiology of LUTS/BPH and ED -- Etiology and Clinical Aspects of LUTS/BPH and ED -- Second-Line Evaluation -- Treatment of LUTS/BPH and ED -- Education and Lifestyle Modifications -- Phosphodiesterase Type 5 Inhibitors -- Tadalafil -- Efficacy of Action of PDE5I Monotherapy in ED-LUTS/BPH -- Combined Therapy With α-Adrenergic Antagonists and PDE5i -- Other PDE5I Therapies (Not Approved by Current Guidelines for ED-LUTS/BPH) -- Sildenafil -- Vardenafil -- Avanafil -- Mirodenafil -- Udenafil -- Effects of Drugs Used for LUTS on Erectile Function -- Conclusive Remarks -- References -- Chapter 5: Metabolic Syndrome and LUTS/BPH -- Introduction -- Metabolic Syndrome: Definition and Prevalence -- MetS and BPH: Preclinical Evidences and Pathophysiology -- MetS and LUTS/BPE: The Role of Inflammation -- Prostate Size and Shape: The Influence of MetS -- The Correlation Between MetS and LUTS -- Diet and Lifestyle in Men With MetS and LUTS Due to BPE -- Basis for Medical Treatment in Men With MetS and LUTS/BPE -- The Impact of MetS on the Outcomes of BPH Surgery -- Conclusions -- References -- Chapter 6: Diagnostic Work-up of LUTS/BPH: From Standard to New Perspectives -- Introduction -- Diagnostic Workup of LUTS/BPH -- Standard Diagnostic Tests -- History -- Symptom Questionnaires -- Frequency Volume Charts and Bladder Diaries -- Physical Examination and Digital-Rectal Examination -- Urinalysis -- Blood Analysis. , PVR Urine -- Uroflowmetry -- Imaging -- Urethro-Cystoscopy -- Computer-Urodynamic Investigation -- New Diagnostic Perspectives -- Ultrasound Measurement of IPP -- Ultrasound Measurement of DWT -- References -- Further Reading -- Chapter 7: Phytotherapy in Benign Prostatic Hyperplasia -- Introduction -- Serenoa Repens -- Mechanism of Action -- Variability of Products and Extraction Techniques -- Clinical Studies -- Safety Profile -- Conclusion -- Pygenum Africanum -- Mechanism of Action -- Clinical Studies -- Safety Profile -- Conclusion -- Urtica Dioica -- Mechanism of Action -- Clinical Studies -- Safety Profile -- Conclusion -- Cucurbita Pepo -- Mechanism of Action -- Clinical Studies -- Safety Profile -- Hypoxis Rooperi -- Mechanism of Action -- Clinical Studies -- Safety Profile and Conclusion -- Rye Grass Pollen -- Mechanism of Action -- Clinical Studies -- Safety Profile and Conclusion -- Conclusion -- References -- Chapter 8: Medical Aspects of the Treatment of LUTS/BPH: Alpha-Blockers -- Introduction -- Pathophysiology and Mechanisms of Action of Alpha-Blockers in BPH -- Pathophysiology of LUTS/BPH/BPO: Reviewing Alpha-Adrenoreceptors as a Valuable Therapeutic Target -- Potential Action of Alpha-Blockers on BPO -- Potential Effects of Alpha-Blockers on Storage Symptoms and Bladder Function -- Potential Effects of Alpha-Blockers on Nocturia -- Types of Alpha-Adrenergic Blockers: Family Members -- Efficacy -- Global Efficacy on LUTS (IPSS), Quality of Life, and Placebo Effect -- Effects on BPO (Qmax, Urodynamics, and Postvoid Residuals) -- Efficacy on the Long Term and Treatment Adherence -- Intermittent Treatment -- Dose Adjustments -- Safety and Tolerability -- Clinical Use -- General Indications/Single Therapy -- Associations -- Conclusion -- References. , Chapter 9: Medical Aspects of the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: 5-Alpha Reducta ... -- Mechanism of Action -- Testosterone and Dihydrotestosterone -- 5-Alpha Reductase Enzyme Family -- Rationale for 5-Alpha Reductase Inhibition in BPH -- 5-Alpha Reductase Inhibitors -- Finasteride -- Dutasteride -- 5-ARI for the Treatment of BPH -- Indications for Treatment of BPH With 5-ARI -- Clinical Effects of BPH Treatment With 5-ARI -- Finasteride Versus Dutasteride for the Treatment of BPH -- Sexual Side Effects of 5-Alpha Reductase Inhibitor Use -- Combination Therapy With 5-ARI and Alpha-1 Adrenergic Receptor Blockers for the Treatment of BPH -- 5-ARI for Hematuria and Bleeding During Transurethral Resection of the Prostate in Men With BPH -- 5-ARI for the Prevention and Treatment of Prostate Cancer -- 5-Alpha Reductase Inhibition for the Prevention of Prostate Cancer -- 5-Alpha Reductase Inhibition for the Treatment of Prostate Cancer -- References -- Chapter 10: Medical Aspects of the Treatment of LUTS/BPH: Antimuscarinic and β3-Agonists -- Keypoints -- Introduction -- Antimuscarinics -- Mechanism of Action -- Efficacy -- Adverse Events -- β3-Agonists -- Mechanism of Action -- Efficacy -- Adverse Events -- Conclusions -- References -- Chapter 11: Medical Aspects of the Treatment of LUTS/BPH: Combination Therapies -- Introduction -- AB+5ARI -- Anticholinergic Agents and AB -- Tolterodine and AB -- Solifenacin Succinate and AB -- Fesoterodine and AB -- β3-Adrenoreceptor Agonist Mirabegron and AB -- Phosphodiesterase-Type-5 Inhibitors and 5ARI or AB -- Plant Extracts/Phytotherapy and Other Agents -- References -- Chapter 12: Surgical Management of LUTS/BPH: TURP vs. Open Prostatectomy -- History of Surgical Treatment for Benign Prostatic Hyperplasia (BPH) -- Pathophysiology of BPH. , Epidemiology and Socioeconomic Burden of Surgical Treatment for BPH -- Factors Affecting Choice of Surgery Type -- Prostate Size -- Surgeon Preference and Hospital Setting -- Patient Age -- Prostatectomy -- Simple Prostatectomy -- Robot-Assisted Laparoscopic Approaches -- TUR of the Prostate -- Monopolar TURP -- Bipolar TURP -- Outcomes -- Symptoms -- Dysuria -- Urgency -- IPSS Improvement -- Quality of Life -- Physiological Measures -- Peak Flow Rate Improvement -- Residual Urinary Volume Reduction -- Perioperative Outcomes -- Bleeding -- Resected Prostate Weight -- Postoperative Fever -- Time to Catheter Removal -- Hospital Stay and Return Time to Work -- Urinary Tract Infection -- Epididymitis -- Retreatment Rate -- Re-operation -- Adverse Events -- Incontinence -- Impotence -- Bladder Neck Contracture -- TUR Syndrome -- Conclusion -- References -- Chapter 13: Surgical Treatment for LUTS/BPH: Laser Devices -- Introduction -- Lasers Typically Used for Vaporization -- GreenLight Laser -- Diode Lasers -- Lasers Typically Used for Resection/Enucleation -- Thulium Lasers -- Holmium:YAG Lasers -- Enucleation for BPO: Techniques and Results -- Holmium Laser Enucleation of the Prostate -- Principles of Surgical Technique -- Results -- Complications -- Thulium Laser Enucleation of the Prostate (ThuLEP) -- Principles of Surgical Technique -- Results -- Complications -- Greenlight Laser Enucleation of the Prostate (GreenLEP) -- Principles of Surgical Technique -- Results -- Complications -- Learning Curve -- Diode Laser Enucleation of the Prostate (DiLEP) -- Principles of Surgical Technique -- Results -- Complications -- Learning Curve -- Eraser Laser Enucleation of the Prostate (ELEP) -- Principles of Surgical Technique -- Results -- Complications -- Laser Ablation for Benign Prostatic Enlargement: Techniques and Results. , Holmium Laser Ablation of the Prostate.

Additional Edition: ISBN 0-12-811397-9

Language: English